[The recombinant vaccinia viruses expressing HPV type 16 wild or mutant E7 protein elicit immunity against tumor cells in mice].
OBJECTIVE
To select mutants of HPV 16 E7 suitable for vaccine development.


METHODS
Several recombinant vaccinia viruses (VwE7, VmE7-1, and VmE7-2) expressing wild E7 or its mutants, ME7-1 (24G26G) and ME7-2 (24G26G91G) respectively, were employed to study their antigenicity and anti tumor activity.


RESULTS
Both VmE7-1 and VwE7 could elicit cytotoxic T lymphocytes (CTL)and protect mice against tumor cells challenge, but VmE7-2 could not induce the immune reactions compared with VmE7-1 and VwE7.


CONCLUSIONS
It suggested that ME7-1 could be used to develop a therapeutic vaccine for cervical cancer.
Zhi
H
H
Institute of Virology, Chinese Academy of Preventive Medicine, Beijing 10052, China.
Han
L
L
Ren
J
J
Tian
H W
HW
Lao
W F
WF
Liang
Y
Y
Ruan
L
L
D000818:Animals; D019496:Cancer Vaccines / Q000494:pharmacology / Q000627:therapeutic use; D003001:Cloning, Molecular; D005260:Female; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D016254:Mutagenesis, Insertional; D009856:Oncogene Proteins, Viral / Q000096:biosynthesis / Q000235:genetics*; D027383:Papillomaviridae / Q000235:genetics*; D050725:Papillomavirus E7 Proteins; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000628:therapy; D014616:Vaccinia virus / Q000235:genetics*
D019496:Cancer Vaccines; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D011994:Recombinant Proteins; C059731:oncogene protein E7, Human papillomavirus type 16